HRP20201165T1 - Uporaba inhibitora ccr3 - Google Patents
Uporaba inhibitora ccr3 Download PDFInfo
- Publication number
- HRP20201165T1 HRP20201165T1 HRP20201165TT HRP20201165T HRP20201165T1 HR P20201165 T1 HRP20201165 T1 HR P20201165T1 HR P20201165T T HRP20201165T T HR P20201165TT HR P20201165 T HRP20201165 T HR P20201165T HR P20201165 T1 HRP20201165 T1 HR P20201165T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- chloride
- eosinophilic
- use according
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Structure Of Transmissions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162937 | 2012-04-03 | ||
| EP13713199.1A EP2833884B1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
| PCT/EP2013/056864 WO2013149986A1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201165T1 true HRP20201165T1 (hr) | 2020-12-11 |
Family
ID=48040249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201165TT HRP20201165T1 (hr) | 2012-04-03 | 2013-04-02 | Uporaba inhibitora ccr3 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20130261153A1 (enExample) |
| EP (3) | EP3763369B1 (enExample) |
| JP (2) | JP2015512432A (enExample) |
| KR (5) | KR20140144200A (enExample) |
| CN (2) | CN104220073A (enExample) |
| AU (1) | AU2013245027B2 (enExample) |
| BR (1) | BR112014023795B1 (enExample) |
| CA (1) | CA2869269C (enExample) |
| CL (1) | CL2014002523A1 (enExample) |
| CY (1) | CY1123222T1 (enExample) |
| DK (1) | DK2833884T3 (enExample) |
| EA (1) | EA032263B1 (enExample) |
| ES (2) | ES2987267T3 (enExample) |
| HR (1) | HRP20201165T1 (enExample) |
| HU (1) | HUE051648T2 (enExample) |
| IL (1) | IL234262A (enExample) |
| IN (1) | IN2014DN06989A (enExample) |
| LT (1) | LT2833884T (enExample) |
| MX (1) | MX2014011786A (enExample) |
| NZ (1) | NZ628882A (enExample) |
| PH (1) | PH12014502239A1 (enExample) |
| PL (1) | PL2833884T3 (enExample) |
| PT (1) | PT2833884T (enExample) |
| RS (1) | RS60665B1 (enExample) |
| SI (1) | SI2833884T1 (enExample) |
| SM (1) | SMT202000499T1 (enExample) |
| WO (1) | WO2013149986A1 (enExample) |
| ZA (1) | ZA201406082B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| US11045284B2 (en) | 2016-11-24 | 2021-06-29 | Kirishima Seiko Co., Ltd. | Dental brace and method for attaching dental brace |
| BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
| ES3046717T3 (en) * | 2017-04-05 | 2025-12-02 | Alkahest Inc | Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors |
| US20190111042A1 (en) * | 2017-10-13 | 2019-04-18 | Alkahest, Inc. | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR-Inhibitors |
| US11426399B2 (en) | 2018-05-15 | 2022-08-30 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
| EP3856195A4 (en) * | 2018-09-26 | 2022-06-22 | Alkahest, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS |
| US20230312697A1 (en) | 2020-06-11 | 2023-10-05 | Alkahest Inc. | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
| AU2022376563A1 (en) | 2021-11-01 | 2023-12-07 | Alkahest, Inc. | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| BRPI0108923B8 (pt) * | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| WO2006083390A2 (en) * | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| US8008092B2 (en) * | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| US8778616B2 (en) * | 2009-05-26 | 2014-07-15 | University Of Kentucky Research Foundation | Method of using CCR3 binding agents to detect choroidal neovascularization |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2020115836A1 (ja) * | 2018-12-05 | 2020-06-11 | 東浜工業株式会社 | ブロワー装置 |
-
2013
- 2013-03-27 US US13/851,564 patent/US20130261153A1/en not_active Abandoned
- 2013-04-02 KR KR1020147027679A patent/KR20140144200A/ko not_active Ceased
- 2013-04-02 ES ES20174399T patent/ES2987267T3/es active Active
- 2013-04-02 AU AU2013245027A patent/AU2013245027B2/en active Active
- 2013-04-02 SM SM20200499T patent/SMT202000499T1/it unknown
- 2013-04-02 CN CN201380016333.7A patent/CN104220073A/zh active Pending
- 2013-04-02 EP EP20174399.4A patent/EP3763369B1/en active Active
- 2013-04-02 CA CA2869269A patent/CA2869269C/en active Active
- 2013-04-02 LT LTEP13713199.1T patent/LT2833884T/lt unknown
- 2013-04-02 BR BR112014023795-6A patent/BR112014023795B1/pt active IP Right Grant
- 2013-04-02 JP JP2015503847A patent/JP2015512432A/ja active Pending
- 2013-04-02 EA EA201401083A patent/EA032263B1/ru unknown
- 2013-04-02 CN CN201910406245.7A patent/CN110384699A/zh active Pending
- 2013-04-02 NZ NZ628882A patent/NZ628882A/en unknown
- 2013-04-02 ES ES13713199T patent/ES2811554T3/es active Active
- 2013-04-02 HR HRP20201165TT patent/HRP20201165T1/hr unknown
- 2013-04-02 PT PT137131991T patent/PT2833884T/pt unknown
- 2013-04-02 KR KR1020217015686A patent/KR20210063481A/ko not_active Ceased
- 2013-04-02 MX MX2014011786A patent/MX2014011786A/es unknown
- 2013-04-02 HU HUE13713199A patent/HUE051648T2/hu unknown
- 2013-04-02 EP EP24158785.6A patent/EP4389217A3/en active Pending
- 2013-04-02 PL PL13713199T patent/PL2833884T3/pl unknown
- 2013-04-02 WO PCT/EP2013/056864 patent/WO2013149986A1/en not_active Ceased
- 2013-04-02 KR KR1020227031439A patent/KR20220132012A/ko not_active Ceased
- 2013-04-02 KR KR1020257028220A patent/KR20250133980A/ko active Pending
- 2013-04-02 IN IN6989DEN2014 patent/IN2014DN06989A/en unknown
- 2013-04-02 SI SI201331753T patent/SI2833884T1/sl unknown
- 2013-04-02 EP EP13713199.1A patent/EP2833884B1/en active Active
- 2013-04-02 DK DK13713199.1T patent/DK2833884T3/da active
- 2013-04-02 KR KR1020207011392A patent/KR20200044988A/ko not_active Ceased
- 2013-04-02 RS RS20200868A patent/RS60665B1/sr unknown
-
2014
- 2014-08-19 ZA ZA2014/06082A patent/ZA201406082B/en unknown
- 2014-08-24 IL IL234262A patent/IL234262A/en active IP Right Grant
- 2014-09-24 CL CL2014002523A patent/CL2014002523A1/es unknown
- 2014-10-03 PH PH12014502239A patent/PH12014502239A1/en unknown
- 2014-12-15 US US14/570,298 patent/US20150099783A1/en not_active Abandoned
-
2015
- 2015-11-30 US US14/953,480 patent/US20160081998A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,918 patent/US20170319567A1/en not_active Abandoned
- 2017-12-22 JP JP2017246173A patent/JP2018080183A/ja not_active Withdrawn
-
2020
- 2020-07-23 CY CY20201100678T patent/CY1123222T1/el unknown
- 2020-08-19 US US16/997,772 patent/US20200375971A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201165T1 (hr) | Uporaba inhibitora ccr3 | |
| JO3195B1 (ar) | مشتقات أندوليزين جديدة, وطريقة تحضيرهم والتركيبات الصيدلانية التي تحتوي عليهم لعلاج السرطان | |
| BR112015022861A2 (pt) | inibidores de bromodomínio | |
| EA202090258A2 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
| MX348422B (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| BR102015032361A8 (pt) | Compostos de quinazolina, usos dos mesmos, composição farmacêutica, kit e artigo de manufatura | |
| BR112012017269A2 (pt) | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos | |
| BRPI1009637A2 (pt) | composto, composição e uso de um composto | |
| MX2019015431A (es) | Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
| NZ715747A (en) | Syk inhibitors | |
| CL2011002115A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| CL2014001729A1 (es) | Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer. | |
| BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
| BR112016015365A8 (pt) | composto, composição farmacêutica e uso de um composto | |
| EA201591301A1 (ru) | Новые пиримидиновые и пиридиновые соединения и их применение | |
| UA107951C2 (xx) | Похідні імідазопіридину як інгібітори jak | |
| EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
| GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
| EA201400311A1 (ru) | Аминозамещенные имидазопиридазины | |
| GEP20156318B (en) | Heteroaryl derivatives as alpha7 nachr modulators |